Study S002456

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07629544
Acronym: PANDA-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 840
Start: 2026-06-19
Primary completion: 2027-07-09
Lead sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.
Conditions: Overweight and Obesity
Interventions: DRUG:DA-302168S; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change from baseline in body weight [From baseline to week 40]
The proportion of subjects with a body weight reduction ≥5% from baseline [From baseline to week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.